Publications by authors named "Shellie Berry"
Article Synopsis
- Dacarbazine was used to treat patients with a type of cancer called sarcoma, but it often caused a lot of nausea and low blood cell levels in the past.
- In a new study with 80 patients, they used new medicines to help prevent these side effects while giving the treatment.
- Results showed that 30% of patients had a good response to the treatment, but nausea and serious blood problems still occurred in a higher percentage than hoped for.
Purpose: To report the interim analysis of the phase II single-arm noninferiority trial, testing the upfront use of dexrazoxane with doxorubicin on progression-free survival (PFS) and cardiac function in soft-tissue sarcoma (STS).
Patients And Methods: Patients with metastatic or unresectable STS who were candidates for first-line treatment with doxorubicin were deemed eligible. An interim analysis was initiated after 33 of 65 patients were enrolled.
Lessons Learned: Ablation therapy appears to be a reasonably safe and effective approach to obtain a significant treatment-free interval for a subset of patients with limited sites of metastatic disease for which systemic control can be obtained with six cycles of chemotherapy.
Background: Metastatic sarcoma often becomes resistant to treatment by chemotherapy. There is sometimes prolonged stable disease from active chemotherapy that provides a window of opportunity for an intervention to prolong disease-free survival.